SCHEIBLER LUKAS has filed 12 insider transactions across 1 company since January 2023.
Most recent transaction: a option exercise of 10000 shares of Apellis Pharmaceuticals, Inc. ($APLS) on December 01, 2023.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | SCHEIBLER LUKAS | Chief Research Officer | M | Common Stock | 10000 | $13.85 | 78,299.0000 | 106,114,000 | 14.64% | 0.01% |
| Dec. 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | SCHEIBLER LUKAS | Chief Research Officer | S | Common Stock | 10000 | $60.00 | 68,299.0000 | 106,114,000 | 12.77% | 0.01% |
| Dec. 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | SCHEIBLER LUKAS | Chief Research Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 39,391.0000 | 106,114,000 | 20.25% | 0.01% |
| Sept. 6, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | SCHEIBLER LUKAS | Chief Research Officer | S | Common Stock | 1756 | $43.01 | 68,299.0000 | 106,114,000 | 2.51% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | SCHEIBLER LUKAS | Chief Research Officer | A | Common Stock | 9886 | $0.00 | 70,358.0000 | 106,114,000 | 16.35% | 0.01% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | SCHEIBLER LUKAS | Chief Research Officer | F | Common Stock | 715 | $58.50 | 69,643.0000 | 106,114,000 | 1.02% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | SCHEIBLER LUKAS | Chief Research Officer | A | Stock Option (Right to Buy) | 14023 | $0.00 | 14,023.0000 | 106,114,000 | 9999.99% | 0.01% |
| Feb. 10, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | SCHEIBLER LUKAS | Chief Research Officer | F | Common Stock | 678 | $51.21 | 60,472.0000 | 106,114,000 | 1.11% | 0.00% |
| Jan. 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | SCHEIBLER LUKAS | Chief Research Officer | F | Common Stock | 542 | $52.77 | 61,150.0000 | 106,114,000 | 0.88% | 0.00% |
| Jan. 20, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | SCHEIBLER LUKAS | Chief Research Officer | F | Common Stock | 2015 | $52.05 | 61,692.0000 | 106,114,000 | 3.16% | 0.00% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | SCHEIBLER LUKAS | Chief Research Officer | A | Common Stock | 22580 | $0.00 | 63,707.0000 | 106,114,000 | 54.90% | 0.02% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | SCHEIBLER LUKAS | Chief Research Officer | A | Stock Option (Right to Buy) | 35472 | $52.66 | 35,472.0000 | 106,114,000 | 9999.99% | 0.03% |